Posted by Michael Wonder on 30 Aug 2021
FDA grants breakthrough device designation for ImpediMed's SOZO digital health platform for renal failure
30 August 2021 - FDA recognises potential of SOZO digital health platform to assist clinicians in measuring exact fluid volume of patients undergoing dialysis.
ImpediMed Limited today announced that the SOZO digital health platform was designated a breakthrough device by the FDA for a proposed indication in renal failure.
